Trial · NCT01639599
Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients
NCT01639599, Not applicable, Completed, The Catholic University of Korea; results first posted 2020-08-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients. Trials, record NCT01639599. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01639599
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients
- NCT number
- NCT01639599
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 150 participants, actual
- Lead sponsor
- The Catholic University of Korea
- Conditions
- Gynecological Disease
- Interventions
- Dexamethasone iv injection, Dexamethasone, haloperidol, Dexamethasone, haloperidol
- First posted
- 2012-07-12
- Last updated
- 2020-09-09
- Results first posted
- 2020-08-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Postoperative Nausea and Vomiting | postoperative 24 hours | incidence of nausea, vomiting and requirement for rescue antiemetics |
| Secondary | Incidence of Extrapyramidal Symptoms | postoperative 24 hours | |
| Secondary | Incidence of Cardiac Arrhythmia | postoperative 2 hours | cardiac arrhythmia on continuous standard lead EKG monitoring |
| Secondary | Sedation Change in Recovery Room | postoperative 30, 60, 90, and 120 min | measurement of sedation change using a visual analogue scale (visual analogue scale; the minimum: 0 = widely awake and the maximum: 10 = maximally asleep) |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Postoperative Nausea and Vomiting | postoperative 24 hours | participants | NUMBER | |
| SECONDARY | Incidence of Extrapyramidal Symptoms | postoperative 24 hours | participants | NUMBER | |
| SECONDARY | Incidence of Cardiac Arrhythmia | postoperative 2 hours | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Sedation Change in Recovery Room | postoperative 30, 60, 90, and 120 min | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Postoperative Nausea and Vomiting | Dexamethasone | 21 | participants | ||
| Incidence of Postoperative Nausea and Vomiting | Dexamethasone, Haloperiol 1mg | 11 | participants | ||
| Incidence of Postoperative Nausea and Vomiting | Dexamethasone + Haloperidol 2mg | 10 | participants | ||
| Incidence of Extrapyramidal Symptoms | Dexamethasone | 0 | participants | ||
| Incidence of Extrapyramidal Symptoms | Dexamethasone, Haloperiol 1mg | 0 | participants | ||
| Incidence of Extrapyramidal Symptoms | Dexamethasone + Haloperidol 2mg | 0 | participants | ||
| Incidence of Cardiac Arrhythmia | Dexamethasone | 0 | Participants | ||
| Incidence of Cardiac Arrhythmia | Dexamethasone, Haloperiol 1mg | 0 | Participants | ||
| Incidence of Cardiac Arrhythmia | Dexamethasone + Haloperidol 2mg | 0 | Participants | ||
| Sedation Change in Recovery Room | Dexamethasone | postoperative 30 min | 4.6 | Standard Deviation 1.3 | score on a scale |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dexamethasone | 50 | |
| Overall Study | STARTED | Dexamethasone, Haloperiol 1mg | 50 | |
| Overall Study | STARTED | Dexamethasone + Haloperidol 2mg | 50 | |
| Overall Study | COMPLETED | Dexamethasone | 50 | |
| Overall Study | COMPLETED | Dexamethasone, Haloperiol 1mg | 49 | |
| Overall Study | COMPLETED | Dexamethasone + Haloperidol 2mg | 50 | |
| Overall Study | NOT COMPLETED | Dexamethasone | 0 | |
| Overall Study | NOT COMPLETED | Dexamethasone, Haloperiol 1mg | 1 | |
| Overall Study | NOT COMPLETED | Dexamethasone + Haloperidol 2mg | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dexamethasone | ||
| Total, all-cause mortality | Dexamethasone, Haloperiol 1mg | ||
| Total, all-cause mortality | Dexamethasone + Haloperidol 2mg | ||
| Total, other adverse events | Dexamethasone | 0 | 50 |
| Total, other adverse events | Dexamethasone, Haloperiol 1mg | 0 | 49 |
| Total, other adverse events | Dexamethasone + Haloperidol 2mg | 0 | 50 |
| Total, serious adverse events | Dexamethasone | 0 | 50 |
| Total, serious adverse events | Dexamethasone, Haloperiol 1mg | 0 | 49 |
| Total, serious adverse events | Dexamethasone + Haloperidol 2mg | 0 | 50 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26152218 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01639599
GET https://conductscience.org/api/trials/v1/NCT01639599/results?page=2